The observation of improvement of insulin resistance and protection of islets and insulin secretion after treatment with antibodies against SeP suggests that targeting this protein may be a new approach to treat MASLD and various metabolic disorders [44]. Here, SELENOP is linked to metabolic dysfunction-associated steatotic liver disease.